LMS - Leiomyosarcoma, Uterine Leiomyosarcoma
Conditions
Brief summary
The purpose of this study is to find out if giving a dose of heated chemotherapy in the abdomen immediately after surgery that is done to remove uterine leiomyosarcoma type of cancer will help lower the risk of the cancer coming back in the future.
Detailed description
Primary Objective: \- To assess the efficacy of cytoreductive surgery with gemcitabine HIPEC followed by postoperative systemic chemotherapy with dacarbazine in subjects with locally recurrent uterine LMS. Secondary Objectives: * To assess the safety of cytoreductive surgery with gemcitabine HIPEC in subjects with locally recurrent uterine LMS. * To assess the 6 month and 12 month intraabdominal relapse free survival in subjects with locally recurrent uterine LMS * To determine quality of life prior to therapy (within 28 days prior to surgery with HIPEC), 4 to 6 weeks after surgery with HIPEC, and then at Cycle
Interventions
DRUGGemcitabine
Hyperthermic intraperitoneal chemotherapy (HIPEC) with gemcitabine. Gemcitabine will be instilled at a dose of 1000 mg/m2 for 60 minutes at temperatures of 42° to 43°C.
DRUGDacarbazine
Dacarbazine 1000 mg/m2 IV every 3 weeks x 6 cycles given IV
PROCEDURECytoreductive Surgery
Surgery for cancer removal
BEHAVIORALFunctional Assessment of Cancer Therapy (FACT) G questionnaire
Preoperative and Postoperative FACT G questionnaire to assess QoL
PROCEDUREComputed Tomography (CT) or Magnetic Resonance Imaging (MRI) Scan
Radiologic imaging after Cycle 3 and 6 and at each follow up visit
DRUGGadolinium
Contrast Agent
Sponsors
Stanford University
Study design
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT
Masking
NONE
Eligibility
Sex/Gender
FEMALE
Age
18 Years to No maximum
Healthy volunteers
No
Inclusion criteria
1. Histologically confirmed diagnosis of uterine leiomyosarcoma (LMS) with evidence of local recurrence. 2. Imaging provides evidence of locally recurrent uterine LMS. 3. Candidate for potentially radical, maximal effort cytoreductive surgery at the discretion and expertise of the treating physician. 4. Age ≥ 18 years. 5. Life expectancy \> 3 months. 6. Women of childbearing potential (WOCBP) will have a negative pregnancy test ≤ 7 days prior to surgery (this test can be omitted if subject is post menopausal by either surgery or elevated FSH) 7. Eastern Cooperative Oncology Group (ECOG) Performance Status ≤ 2. 8. Hemoglobin (HGB) ≥ 9 g/dL. 9. White blood cell count (WBC) ≥ 3.0 K/ul. 10. Absolute neutrophil count (ANC) ≥ 1.5 K/ul. 11. Platelets (PLT) ≥ 100 K/ul. 12. Total bilirubin within normal institutional limits. 13. Serum glutamic oxaloacetic transaminase (SGOT/Serum glutamic pyruvic transaminase (SGPT) \< 2.5 x institutional upper limit of normal (ULN). 14. Creatinine \< 1.5 x ULN or creatinine clearance \> 60 mL/min according to Cockroft Gault formula. 15. Prothrombin Time (PT) such that international normalized ratio (INR) is \< 1.5 (or an in range INR, usually between 2 and 3, if a subject is on a stable dose of therapeutic warfarin or low molecular weight heparin) and a partial thromboplastin time (PTT) \< 1.2 times control. 16. Serum albumin ≥ 2.5 g/dL. 17. Ability to understand and the willingness to personally sign the written IRB approved informed consent document. Note that this study does not allow the use of a legally authorized representative
Exclusion criteria
1. Recurrence of LMS within less than 6 months after the last dose of gemcitabine. 2. Active extra abdominal disease including active malignant pleural effusion. Subjects who have been successfully treated with neoadjuvant chemotherapy and no longer have (malignant) pleural effusions may be included. 3. Prior gemcitabine given in non adjuvant setting. 4. Prior treatment with dacarbazine. 5. Active infection requiring antibiotics. 6. Unresolved toxic effects of prior therapy (except alopecia). Resolution is considered ≤ Grade 1 per NCI CTCAE, version 5.0. 7. Pregnant. 8. Breast feeding. 9. Presence of metastatic liver disease
Design outcomes
Primary
| Measure | Time frame | Description |
|---|---|---|
| Progression free survival (PFS) | 1 year | Progression free survival as measured from the time of surgery until death or disease progression. |
Secondary
| Measure | Time frame | Description |
|---|---|---|
| Rate of Grade 4 infections | 30 days post surgery with gemcitabine HIPEC | Rate of Grade 4 infections within 30 days post surgery with gemcitabine HIPEC will be assessed using CTCAE version 5.0. |
| Intraabdominal relapse free survival | 6 months | Relapse free survival as measured from time of surgery until intraabdominal recurrence |
| Overall Functional Assessment of Cancer Therapy: General (FACT G) score | Baseline, 4 to 6 weeks post-surgery with HIPEC | Difference in overall FACT G score from baseline to 4 to 6 weeks post-surgery with gemcitabine HIPEC. FACT G is a quality of life questionnaire composed of 27 items divided into four main quality of life categories: Physical Well Being (PWB); Social/Family Well Being (SWB); Emotional Well Being (EWB); and Functional Well Being (FWB). Total FACT G score is obtained by summing the scores from the four main QoL categories (PWB; SWB; EWB; FWB). The range of the scale is 0-108. Negatively worded items are reverse scored prior to summing so that higher subscale and total scores indicate better Quality of life (Qol). |
Countries
United States
Contacts
PRINCIPAL_INVESTIGATORKristen N Ganjoo, MD
Stanford University
Outcome results
None listed